tirzepatide not available The FDA says the Zepbound shortage is over. That's rattling the weight loss industry FDA confirms end of Eli

For patients unfamiliar with self-injection, this can initially feel daunting, but the technique is straightforward and is routinely taught by healthcare professionals

Quality and concentration vary by compounder

Under discussions tied to the Treat and Reduce Obesity Act, several major commercial insurers expanded GLP-1 obesity coverage in 2025-2026

As a novel GLP-1 receptor agonist, Retatrutide stands out by also targeting another third receptor to potentially amplify its impact on both weight reduction and blood sugar management

Semaglutide is a weight loss drug that targets the glucagon-like peptide-1 (GLP-1), sold by Novo Nordisk under the brand name Wegovy to treat people with obesity and under Ozempic to treat patients with both type 2 diabetes and obesity